Cargando…
Triple negative breast cancer: Pitfalls and progress
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification. It accounts for 10–15% of incident breast cancers and carries the worst prognosis. TNBC is overrepresented among Black and pre-menop...
Autores principales: | Zagami, Paola, Carey, Lisa Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392735/ https://www.ncbi.nlm.nih.gov/pubmed/35987766 http://dx.doi.org/10.1038/s41523-022-00468-0 |
Ejemplares similares
-
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022) -
Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
por: Amos, Keith D., et al.
Publicado: (2012) -
Triple-negative breast cancer molecular subtyping and treatment progress
por: Yin, Li, et al.
Publicado: (2020) -
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020) -
Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)